Sign in
Taking peopleNo phase

Sleep therapy for young people with insomnia, looking at impulsive and risky behaviour

Tests talking therapy for insomnia on impulsiveness and risk-taking in young people.

Key facts

Who runs it
The University of Hong Kong
Where
Hong Kong1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Effects of CBT-I on Impulsivity and Risk Taking in Youths With Insomnia
Status
Recruiting
People taking part
124 people, planned
Started
19 Jun 2024
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cognitive Behavioural Therapy for Insomnia
  • Health-related Psychoeducation
Record updated
10 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Chinese young people aged 12-24 with insomnia. It tests whether a talking therapy for insomnia (CBT-I) reduces impulsive and risky behaviour.

Age
12 to 24 years
Sex
All sexes
Disease stage
Insomnia disorder by DSM-V criteria, with an Insomnia Severity Index (ISI) score of 9 or more.
Earlier treatment
People currently getting any psychological treatment for insomnia cannot join. Regular use of medicines that affect sleep (e.g. hypnotics, steroids, melatonin, Traditional Chinese Medicine) is not allowed.

Main reasons for not taking part

  • Current substance abuse or dependence, or past mania, schizophrenia spectrum, neurodevelopmental or organic mental disorders, or intellectual disability
  • Another sleep disorder, such as narcolepsy, breathing problems in sleep or restless leg syndrome
  • A medical condition that disturbs sleep, such as eczema or acid reflux
  • Serious suicidal thoughts with a plan, or a suicide attempt
  • Hearing or speech problems, or night shift work

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Chinese aged 12-24 years old
  • Written informed consent of participation in the study is given by the participant and his/her parent or guardian (for those aged under 18)
  • Willing to comply with the study protocol
  • Meeting the DSM-V diagnostic criteria of insomnia disorder and with a score on Insomnia Severity Index (ISI) >= 9 (suggested cut-off for adolescents)

Who cannot take part

  • Concurrent, regular use of medications(s) known to affect sleep continuity and quality including both western medications (e.g. hypnotics, steroids) and over-the-counter OTC medications (e.g. melatonin, Traditional Chinese Medicine, TCM)
  • Currently receiving any psychological treatment for insomnia
  • A current diagnosis of substance abuse or dependence; a current or past history of manic or hypomanic episode, schizophrenia spectrum disorders, neurodevelopmental disorders, organic mental disorders, or intellectual disabilities
  • Having a prominent medical condition known to interfere with sleep continuity and quality (e.g. eczema, gastro-oesophageal reflux disease)
  • Having a clinically diagnosed sleep disorder (other than insomnia disorder) that may potentially contribute to a disruption in sleep continuity and quality, such as narcolepsy, sleep-disordered breathing, and restless leg syndrome, as ascertained by the Structured Interview for Sleep Patterns and Disorders (DISP), a validated structured diagnostic interview to assess major sleep disorders according to the International Classification of Sleep Disorder (ICSD) criteria
  • In the opinion of the research clinician, having a clinically significant suicidality (presence of suicidal ideation with a plan or an attempt)
  • With hearing or speech deficit
  • Night shift worker

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 24 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Insomnia is prevalent in adolescents. Impulsive behaviours and excessive risk-taking have been linked to the manifestation of psychopathology in youths. Previous research based on behavioural and neurophysiological measures has found that individuals with insomnia demonstrated impaired inhibitory control, which is associated with detrimental outcomes such as substance abuse and self-harm.

Read full original descriptionShow less

Existing evidence has shown some positive effects of cognitive behavioural therapy for insomnia (CBT-I) on insomnia symptoms and daytime functioning in youths. Given the link between insomnia and impulsivity reported in previous research, and sleep as a highly modifiable factor, we are conducting this randomised controlled trial to examine the impact of CBT-I in improving impulsivity and risk-taking in youth with insomnia.

The 2 groups in the trial

  • CBT-ITreatment being tested

    N = 62

    Treatment: Cognitive Behavioural Therapy for Insomnia

  • Health-related Psychoeducation controlExisting treatment, for comparison

    N = 62

    Treatment: Health-related Psychoeducation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effects of Cognitive Behavioural Therapy for Insomnia (CBT-I) on Impulsivity and Risk Taking in Youths With Insomnia: A Randomised Controlled Trial
Plain-language title
Sleep therapy for young people with insomnia, looking at impulsive and risky behaviourGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07399964, who can take part
Record updated
10 February 2026